Donald Hunninghake, M.D.

Professor Emeritus, Departments of Medicine & Pharmacology

M.D. University of Kansas, Kansas City, Kansas, 1955-1959

Internship: University of Kansas, Kansas City, Kansas, 1959-1960

Residency: Internal Medicine, University of Kansas, 1962-65

Fellowship: Clinical Pharmacology (USPHS), University of Kansas, 1964-67

Professional Organizations: American College of Physicians,
American Society for Pharmacology and Experimental Therapeutics,
American Heart Association, American College of Clinical, Pharmacology, American Federation for Clinical Research, Society for Clinical Trials, American Association for the Advancement of Science

Recent Publications:
Hunninghake DB, McGovern ME, Koren M, Brazg R, Murdock D, Weiss S, Pearson T. A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. Clin Cardiol 2003;26 (3):112-118.

Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals – [Article] Am J Cardiol 2003;91 (5A Suppl S):11C-17C.

Davidson MH, Wood DA, Paoletti R, Hobbs R, Shepherd J, Brown WV, Hunninghake DB, McKenney JM. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals – Discussion. [Editorial Material]. Am J Cardiol 2003;91 (5A):17C-19C.

Knatterud GL, C. White, Geller NL, Campeau L, Forman SA, Domanski M, Forrester JS, Gobel FL, Herd JA, A. Hickey, Hoogwerf BJ, Hunninghake DB, Terrin ML, and Rosenberg Y. Angiographic changes in saphenous vein grafts are predictors of clinical outcomes. Am Heart J 2003;145 (2):262-269.

Isaacsohn J, Hunninghake D, Schrott H, Dujovne CA, Knopp R, Weiss SR, H. Bays, Crouse (III) R, Davidson MH, Keilson LM, J. McKenney, Korenman SG, Dobs AS, Stein E, Krauss RM, D. Maccubbin, M. Cho, Plotkin DJ, Mitchel YB. Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia. Clin Cardiol 2003;26 (1):18-24.

Hunninghake DB, Ballantyne CM, Maccubbin DL, Shah SK, Gumbiner B, Mitchel YB. Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. Clin Ther 2003;25 (6):1670-1686,.

Lindquist R, Dupuis G, Terrin ML, Hoogwerf B, Czajkowski S, Herd JA, Barton FB, Tracy FM, Hunninghake DB, Treat-Jacobson D, Shumaker S, Zyzanski S, Goldenberg I, Knatterud GL. Comparison of health-related quality-of-life outcomes of men and women after coronary artery bypass surgery through 1 year: findings from the POST CABG Biobehavioral Study. Am Heart J 2003;146 (6):1038-1044.

Hunninghake DB, Stein EA, Bays HE, Rader DJ, Chitra RR, Simonson SG, Schneck DW. Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia. Coron Artery Dis. 2004;15 (2):115-123.